Overview
Nucyrna Therapeutics aims to address the unmet medical needs in ALS and other CNS disorders through its next-gen RNA-targeting technology. Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology. Demonstrating a remarkable therapeutic index profile in CNS, the company is focused on neurodegenerative diseases.